Literature DB >> 15676013

Effects of diabetes and CETP expression on diet-induced atherosclerosis in LDL receptor-deficient mice.

Jairo A Berti1, Alessandro G Salerno, Eliete J B Bighetti, Andrea C Casquero, Antonio C Boschero, Helena C F Oliveira.   

Abstract

The role of CETP expression and diabetes in atherogenesis was investigated in mice with heterozygous disruption of the LDL receptor gene (LDLR1). LDLR1 mice with and without CETP expression were treated with streptozotocin (STZ) and maintained on a standard diet for one month before switching to an atherogenic diet for an additional month. STZ-sensitive mice had approximately 2.5-fold higher glycemia and 7.5- to 8.0-fold higher cholesterolemia. Factorial analysis of variance showed no significant effect of diabetes, CETP or diabetes-CETP interaction on the size of the atherosclerotic lesions. CETP expression in non-diabetic mice resulted in a 50% reduction in the area of the atherosclerotic lesions. Multiple regression analysis showed a positive and independent atherogenic effect of triglyceridemia in LDLR1 mice and of cholesterolemia in diabetic mice. Logistic analysis showed that elevated plasma cholesterol level significantly increased the risk of developing large lesion size (>75th percentile). In conclusion, CETP expression did not alter the lesion formation in response to diabetes, although it may be protective in the euglycemic state; the triglyceride level was an independent risk factor for LDL receptor-deficient mice but not for CETP-expressing mice; and elevated plasma cholesterol levels increased the risk of developing large atherosclerotic lesions, independently of CETP and diabetes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15676013     DOI: 10.1111/j.1600-0463.2005.apm1130106.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  4 in total

1.  Aggressive very low-density lipoprotein (VLDL) and LDL lowering by gene transfer of the VLDL receptor combined with a low-fat diet regimen induces regression and reduces macrophage content in advanced atherosclerotic lesions in LDL receptor-deficient mice.

Authors:  Erin D MacDougall; Farah Kramer; Patti Polinsky; Shelley Barnhart; Bardia Askari; Fredrik Johansson; Rebecca Varon; Michael E Rosenfeld; Kazuhiro Oka; Lawrence Chan; Stephen M Schwartz; Karin E Bornfeldt
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

2.  Regulation of plasma fructose and mortality in mice by the aldose reductase inhibitor lidorestat.

Authors:  Hye-Lim Noh; Yunying Hu; Tae-Sik Park; Thomas DiCioccio; Andrew J Nichols; Kazue Okajima; Shunichi Homma; Ira J Goldberg
Journal:  J Pharmacol Exp Ther       Date:  2008-10-30       Impact factor: 4.030

3.  Apolipoprotein E4 exaggerates diabetic dyslipidemia and atherosclerosis in mice lacking the LDL receptor.

Authors:  Lance A Johnson; Jose M Arbones-Mainar; Raymond G Fox; Avani A Pendse; Michael K Altenburg; Hyung-Suk Kim; Nobuyo Maeda
Journal:  Diabetes       Date:  2011-08-01       Impact factor: 9.461

4.  Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver.

Authors:  Eliete J B Bighetti; Patrícia R Patrício; Andrea C Casquero; Jairo A Berti; Helena C F Oliveira
Journal:  Lipids Health Dis       Date:  2009-11-23       Impact factor: 3.876

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.